论文部分内容阅读
通过肾癌细胞的体外实验，应用MTT方法，观察了化疗致敏剂搏定对细胞毒药物长春新碱和阿霉素抗RCC－925肾癌细胞效应的体外增效作用．结果发现：RCC－925肾癌细胞系对长春新碱高度耐药，对阿霉素低度耐药，半数致死浓度分别为14726．4μg／ml和1．559μg／ml。异搏定1.25μg／ml即可显著提高长春新碱和阿霉索的细胞毒性，增效幅度随异搏定浓度的升高而增强，增效倍数对长春新碱为1．3×104～1．5×105倍，对阿霉素为3．5～25．1倍。提示异搏定对RCC－925肾癌细胞的多重耐药性具有显著的逆转作用．
In vitro experiments using renal cancer cells, MTT assay was used to observe the synergistic effect of chemotherapeutic sensitizer BDP on cytotoxicity of vincristine and doxorubicin against RCC-925 cells. The results showed that the RCC-925 cell line was highly resistant to vincristine and resistant to doxorubicin. The median lethal concentrations were 14726.4μg / ml and 1.559μg / ml, respectively. Verapamil 1.25μg / ml can significantly increase the vincristine and adriamycin cytotoxicity, synergistic rate with the increase of verapamil concentration increased synergistic times vincristine 1.3 × 104 ~ 1.5 × 105 times for doxorubicin 3.5 ~ 25.1 times. Tip verapamil RCC-925 renal cell carcinoma cell multi-drug resistance has a significant reversal.